Literature DB >> 15548809

Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.

P L Lip1, S Chatterjee, G J Caine, M Hope-Ross, J Gibson, A D Blann, G Y H Lip.   

Abstract

BACKGROUND: Proliferative diabetic retinopathy (PDR) may be a response to abnormal angiogenic growth factors such as vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), and the soluble angiopoietin receptor tie-2. The authors hypothesised the following: (a) there are differences in plasma levels of these growth factors in different grades of diabetic retinopathy; and (b) that the effects of intervention with panretinal laser photocoagulation (PRP) for PDR, and angiotensin receptor blockade (using eprosartan) for patients with other grades of diabetic retinopathy will be to reduce levels of the growth factors.
METHODS: Cross sectional and interventional study (using PRP and eprosartan) in diabetic patients. VEGF, Ang-2, and tie-2 were measured by ELISA.
RESULTS: VEGF (p<0.001) and Ang-2 levels (p<0.001) were significantly higher in 93 diabetic patients compared to 20 healthy controls, with the highest levels in grade 2 and grade 3 diabetic retinopathy (p<0.05). Tie-2 was lower in diabetics compared to controls (p = 0.008), with no significant differences between the diabetic subgroups. Overall, VEGF significantly correlated with Ang-2 (p<0.001) and tie-2 (p = 0.004) but the correlation between Ang-2 and tie-2 levels was not significant (p = 0.065). Among diabetic patients only, VEGF levels were significantly correlated with Ang-2 (p<0.001) and tie-2 (p<0.001); the correlation between Ang-2 and tie-2 levels was also significant (p<0.001). There were no statistically significant effects of laser photocoagulation on plasma VEGF, Ang-2, and tie-2 in the 19 patients with PDR, or any effects of eprosartan in the 28 patients with non-proliferative diabetic retinopathy.
CONCLUSION: Increased plasma levels of VEGF and Ang-2, as well as lower soluble tie-2, were found in diabetic patients. The highest VEGF and Ang-2 levels were seen among patients with pre-proliferative and proliferative retinopathy, but there was no relation of tie-2 to the severity of retinopathy. As the majority of previous research into Ang-2 and tie-2 has been in relation to angiogenesis and malignancy, the present study would suggest that Ang-2 and tie-2 may be used as potential indices of angiogenesis in diabetes mellitus (in addition to VEGF) and may help elucidate the role of the angiopoietin/tie-2 system in this condition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548809      PMCID: PMC1772428          DOI: 10.1136/bjo.2004.048587

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  16 in total

Review 1.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

Authors:  J Holash; S J Wiegand; G D Yancopoulos
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

2.  Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.

Authors:  P L Lip; F Belgore; A D Blann; M W Hope-Ross; J M Gibson; G Y Lip
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-07       Impact factor: 4.799

Review 3.  Vascular endothelial growth factors and angiogenesis in eye disease.

Authors:  A N Witmer; G F J M Vrensen; C J F Van Noorden; R O Schlingemann
Journal:  Prog Retin Eye Res       Date:  2003-01       Impact factor: 21.198

4.  Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1.

Authors:  G J Caine; A D Blann; P S Stonelake; P Ryan; G Y H Lip
Journal:  Eur J Clin Invest       Date:  2003-10       Impact factor: 4.686

Review 5.  The enigmatic role of angiopoietin-1 in tumor angiogenesis.

Authors:  Linda J Metheny-Barlow; Lu Yuan Li
Journal:  Cell Res       Date:  2003-10       Impact factor: 25.617

6.  Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.

Authors:  Lin Zhang; Nuo Yang; Jin-Wan Park; Dionyssios Katsaros; Stefano Fracchioli; Gaoyuan Cao; Ann O'Brien-Jenkins; Thomas C Randall; Stephen C Rubin; George Coukos
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

7.  Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.

Authors:  N A Y Chung; A J Makin; G Y H Lip
Journal:  Eur J Clin Invest       Date:  2003-07       Impact factor: 4.686

8.  Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization.

Authors:  Hitoshi Takagi; Shinji Koyama; Hisayuki Seike; Hideyasu Oh; Atsushi Otani; Miyo Matsumura; Yoshihito Honda
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-01       Impact factor: 4.799

Review 9.  Vascular endothelial growth factor gene regulation and action in diabetic retinopathy.

Authors:  Ming Lu; Anthony P Adamis
Journal:  Ophthalmol Clin North Am       Date:  2002-03

Review 10.  Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.

Authors:  Ruth B Caldwell; Manuela Bartoli; M Ali Behzadian; Azza E B El-Remessy; Mohamed Al-Shabrawey; Daniel H Platt; R William Caldwell
Journal:  Diabetes Metab Res Rev       Date:  2003 Nov-Dec       Impact factor: 4.876

View more
  22 in total

Review 1.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

2.  MicroRNA-126: a promising novel biomarker in peripheral blood for diabetic retinopathy.

Authors:  Li-Li Qin; Mei-Xia An; Yan-Li Liu; Han-Chun Xu; Zhi-Qing Lu
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

3.  Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.

Authors:  Jikui Shen; Maike Frye; Bonnie L Lee; Jessica L Reinardy; Joseph M McClung; Kun Ding; Masashi Kojima; Huiming Xia; Christopher Seidel; Raquel Lima e Silva; Aling Dong; Sean F Hackett; Jiangxia Wang; Brian W Howard; Dietmar Vestweber; Christopher D Kontos; Kevin G Peters; Peter A Campochiaro
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

4.  Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion.

Authors:  Yoav Y Pikkel; Adi Sharabi-Nov; Itzchak Beiran; Joseph Pikkel
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

Review 5.  Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema.

Authors:  Peter A Campochiaro; Kevin G Peters
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

6.  THE AUTODIGESTION HYPOTHESIS AND RECEPTOR CLEAVAGE IN DIABETES AND HYPERTENSION.

Authors:  F A Delano; A Y Chen; K-I S Wu; E D Tran; S F Rodrigues; G W Schmid-Schönbein
Journal:  Drug Discov Today Dis Models       Date:  2011

7.  Effect of pan-retinal laser photocoagulation on plasma VEGF, endothelin-1 and nitric oxide in PDR.

Authors:  Tarek Ahmed Mohamed; Sahar El-Deek Mohamed
Journal:  Int J Ophthalmol       Date:  2010-03-18       Impact factor: 1.779

8.  Effects of laser photocoagulation on serum angiopoietin-1, angiopoietin-2, angiopoietin-1/angiopoietin-2 ratio, and soluble angiopoietin receptor Tie-2 levels in type 2 diabetic patients with proliferative diabetic retinopathy.

Authors:  Qiao-Ying You; Fu-Yuan Zhuge; Qi-Qian Zhu; Xu-Wei Si
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

9.  The Contrary Impact Of Diabetes And Exercise On Endothelial Nitric Oxide Synthase Function.

Authors:  Nazar Labinskyy; Steven Hicks; James Grijalva; John Edwards
Journal:  Webmedcentral       Date:  2010-12-28

10.  Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas.

Authors:  Xinyuan Zhang; Shisan Bao; Donna Lai; Robert W Rapkins; Mark C Gillies
Journal:  Diabetes       Date:  2008-01-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.